Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 165.45M P/E - EPS this Y 28.00% Ern Qtrly Grth -
Income -271.42M Forward P/E -1.44 EPS next Y 32.00% 50D Avg Chg -53.00%
Sales - PEG -0.12 EPS past 5Y - 200D Avg Chg -52.00%
Dividend N/A Price/Book 0.42 EPS next 5Y 12.40% 52W High Chg -75.00%
Recommedations 3.30 Quick Ratio 4.88 Shares Outstanding 52.47M 52W Low Chg 14.00%
Insider Own 5.66% ROA -28.31% Shares Float 31.93M Beta 2.16
Inst Own 78.95% ROE -69.42% Shares Shorted/Prior 2.02M/1.79M Price 3.16
Gross Margin - Profit Margin - Avg. Volume 1,184,417 Target Price 2.90
Oper. Margin - Earnings Date Mar 28 Volume 1,009,541 Change 5.33%
About Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc News
07:32 AM Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results
05:30 AM Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
03/26/24 Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
02/12/24 Following a 25% decline over last year, recent gains may please Kodiak Sciences Inc. (NASDAQ:KOD) institutional owners
02/06/24 Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
01/30/24 Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
01/04/24 Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/14/23 Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
11/21/23 Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/15/23 Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
11/14/23 Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ...
11/14/23 Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
11/06/23 Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
11/03/23 We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
11/01/23 KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
10/11/23 Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
09/13/23 Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?
09/08/23 Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
09/07/23 New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion
09/05/23 Owning 49% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD),
KOD Chatroom

User Image Nibbler Posted - 27 minutes ago

$KOD Just when you think you might recover some on this stock. Same ole Kodiak.

User Image tahloolaaa Posted - 32 minutes ago

$KOD WTF

User Image biomaster22 Posted - 52 minutes ago

$KOD great job as usual Victor, a Sell off of almost 20% just let the baker bros. buy you out. You clearly can't do anything !

User Image tahloolaaa Posted - 1 hour ago

$KOD i didnt think the news was that bad.

User Image epsguid Posted - 3 hours ago

$KOD reported a loss of $1.13, consensus was ($0.86) via @eWhispers #epsmiss http://eps.sh/d/kod

User Image DonCorleone77 Posted - 4 hours ago

$KOD Kodiak Sciences reports Q4 EPS ($1.13), consensus (77c) "We intend to progress our portfolio of three late-stage clinical assets as rapidly as we can into Phase 3 value inflection points," said Victor Perlroth, CEO of Kodiak Sciences. "We were pleased with the Phase 1 study results of KSI-501, our anti-IL-6 and VEGF trap bispecific antibody biopolymer conjugate, in patients with diabetic macular edema ("DME"). The results of this study demonstrated that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved clinically meaningful and sustained visual acuity gains. KSI-501 contains three tiers of innovation: (1) a two-target mechanism potently inhibiting both the dominant VEGF pathway and the IL-6 inflammation pathway, (2) a design based on Kodiak's ABC Platform that we believe holds the potential for 6-month durability in the majority of patients, and (3) an enhanced KSI-501 formulation informed from tarcocimab's commercial manufacturing scale-up...."

User Image Stock_Titan Posted - 4 hours ago

$KOD Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-fourth-rsgeitg9xxx6.html

User Image ThePhil Posted - 11 hours ago

$KOD

User Image Nibbler Posted - 17 hours ago

$KOD Is it alarming that earnings are after the bell on a 3 day weekend ? I thought it was tomorrow morning before the bell. Was that changed?

User Image rlichgolf Posted - 1 day ago

$KOD slow and steady wins the race

User Image Keepkalmnwathdagraf Posted - 1 day ago

$KOD So many room to go…

User Image wtfakker Posted - 1 day ago

$KOD hold up

User Image Kelly12 Posted - 1 day ago

$KOD rise into earnings… they better be great or this drops hard

User Image biomaster22 Posted - 1 day ago

$KOD geothug get lost, how sad are you to only have enough $ to short a 7.00 stock

User Image Cutlass Posted - 1 day ago

$KOD Gap at 50 🔎

User Image JuanTransue161 Posted - 1 day ago

$KOD Uranium demand is rising. Good news for STLNF holders.

User Image Cutlass Posted - 1 day ago

$KOD Nice Day 📈 14%

User Image Kelly12 Posted - 1 day ago

$KOD up into earnings

User Image geothug Posted - 1 day ago

$KOD incredible how this turd keeps pumping.... their pipeline is empty. KS-301 caused cataracts. WTF?

User Image _StockTrader Posted - 1 day ago

Real-Time Stock Data $KOD Price: 6.59 Volume: 231512 Market Cap: 341594688 PE Ratio: -2.0798721 Powered by: JEWL

User Image Stock_Titan Posted - 2 days ago

$KOD Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 https://www.stocktitan.net/news/KOD/kodiak-sciences-to-report-fourth-quarter-and-full-year-2023-qp47pibz22ai.html

User Image Keepkalmnwathdagraf Posted - 3 days ago

$KOD Beautiful new green candle is drawing :)

User Image AnomalyDetective Posted - 5 days ago

Week 12 MDA breakout picks delivered 23.3% returns last week led by peak gains in $VERI +83.7% and $BDTX +27.5% for members in 355 consecutive weeks of testing with minimal cumulative returns of 2,330.5% following the Momentum Gauges®. All new Week 13 MDA picks have been released for members at https://seekingalpha.com/marketplace/1201-value-momentum-breakouts/subscribe with daily MDA breakout picks at: www.vmbreakouts.com and prior picks like $LAC $SERA $KOD continue in Segment 6 MDA conditions.

User Image Nibbler Posted - 5 days ago

$KOD What dat so green?

User Image Cutlass Posted - 5 days ago

$KOD Tricky one 🟩👍📈😊

User Image LonePine1995 Posted - 1 week ago

$KOD bought 8k at open under 5 sold em at 5.80 which was decent resistance two days ago. Can we do it again tomorrow???

User Image tahloolaaa Posted - 1 week ago

$KOD LOL

User Image biomaster22 Posted - 1 week ago

$KOD pathetic !

User Image biomaster22 Posted - 1 week ago

$KOD BS sell off last hour WTF !

User Image Nibbler Posted - 1 week ago

$KOD Dear Felix, What's up?

Analyst Ratings
UBS Neutral Dec 21, 23
Capital One Overweight Nov 17, 23
UBS Neutral Jul 27, 23
Chardan Capital Neutral Jul 25, 23
Barclays Underweight Jul 25, 23
JP Morgan Underweight Jul 25, 23
Jefferies Hold Jul 24, 23
Capital One Equal-Weight Jul 24, 23
JP Morgan Neutral Apr 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
EHRLICH JASON See Remarks See Remarks Jun 14 Sell 9.33 3,390 31,629 61,924 06/16/23
BORGESON JOHN A. See Remarks See Remarks Jun 14 Sell 9.33 4,197 39,158 178,077 06/16/23
EHRLICH JASON See Remarks See Remarks Jun 15 Sell 7.12 3,487 24,827 56,920 06/17/22
BORGESON JOHN A. See Remarks See Remarks Jun 15 Sell 7.12 4,343 30,922 173,755 06/17/22
BAKER BROS. ADVISORS LP Director Director Jun 02 Buy 7.77 572,349 4,447,152 15,967,504 06/06/22
BAKER BROS. ADVISORS LP Director Director May 16 Buy 5.9 456,690 2,694,471 15,142,074 05/18/22
PERLROTH VICTOR Chairman and CEO Chairman and CEO Feb 24 Sell 9.09 1,340,000 12,180,600 2,168,038 02/28/22
BAKER BROS. ADVISORS LP Director Director Feb 15 Buy 54.11 400,965 21,696,216 14,734,965 02/17/22
BAKER BROS. ADVISORS LP Director Director Jan 27 Buy 52.1 347,665 18,113,346 14,364,512 01/31/22
BAKER BROS. ADVISORS LP Director Director Jan 21 Buy 57.62 501,111 28,874,016 14,027,837 01/25/22
EHRLICH JASON See Remarks See Remarks Jan 20 Option 10.29 6,950 71,516 58,491 01/24/22
EHRLICH JASON See Remarks See Remarks Jan 20 Sell 64.9 6,950 451,055 51,541 01/24/22
EHRLICH JASON See Remarks See Remarks Oct 20 Option 10.29 6,950 71,516 58,491 10/22/21
EHRLICH JASON See Remarks See Remarks Oct 20 Sell 112.15 6,950 779,442 51,541 10/22/21
BAKER BROS. ADVISORS LP Director Director Sep 09 Buy 93.12 57,501 5,354,493 13,269,155 09/09/21